Aprocitentan: A New Option for Resistant Hypertension and Its Place in Patient Care

Southern Medical Journal 2026

View at publisher
Authors: Jason Powell, Jim Taylor
DOI: 10.14423/smj.0000000000001972
Cited by: 1
References: 5

Abstract

=0.0046), respectively. Aprocitentan has shown benifit in further reduction of blood pressure for individuals who have failed standard triple therapy, such as a combination of an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, nondihydropyridine calcium channel blocker, and thiazide or thiazide.

Fields of Study & Subjects

Blood Pressure and Hypertension Studies Sodium Intake and Health Heart rate and cardiovascular health

Publication details

Journal / source
Southern Medical Journal
Publisher
Southern Medical Association
Volume
119
Issue
6
Pages
299–302
Publication date
1 June 2026
Language
EN